Every year, twenty thousand men will die of prostate cancer, the second primary cause of cancer mortality among men in the United States. While there are currently many approved prostate cancer drugs contributing to high ten-year survival rates (99%), there is a lack of chemotherapeutic treatments for metastatic castrate-resistant prostate cancers, which have a ten-year survival rate of 28% (1, 2). Novel drugs targeting metal homeostasis open an unexplored realm for chemotherapy. Disulfiram has been shown to inhibit metastatic castrate-resistant tumor growth via a copper dependent mechanism (3). However, disulfiram lacks specificity to cancer and induces apoptosis and protein inactivation in non-malignant cells. Copper prochelators based on active component of disulfiram that is targeted to prostate cancer cells can help minimize the non-specific activity and side effects, thus acting as targeted prodrugs. Design, synthesis, and efficacy of the prostate cancer targeted prodrug will be discussed in the presentation.<br/><br/>

Prostate cancer targeted prodrug based on copper prochelator

254th National Meeting (2017)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.